



Benefits of using FreeStyle Libre with GLP-1 therapy

November 2023

Overview and Conclusions

Overview:

- Conducted a large, real-world study to evaluate whether adding FreeStyle Libre to GLP-1 therapy further improves HbA1c
- Study included people with Type 2 diabetes who were already using a GLP-1 and had an elevated HbA1c level ($\geq 8\%$) at the time they first started using FreeStyle Libre

Conclusions:

- Patients who were already using a GLP-1 saw a significant improvement in HbA1c after adding FreeStyle Libre
- Average HbA1c improvement of 1.5 points
- Improvement in HbA1c seen:
 - Regardless of the time gap between starting GLP-1 therapy and adding FreeStyle Libre
 - Across all GLP-1 products
 - In insulin and non-insulin users

Study Design

Data Source:


- Optum's de-identified Market Clarity Data, a linked electronic health records (EHR)-claims database

Inclusion criteria:

- Adults (18+ years of age)
- Type 2 diabetes diagnosis between 2018-2022
- Elevated HbA1c ($\geq 8\%$) at the time of starting to use FreeStyle Libre
- Active user of GLP-1 therapy, defined by having at least one GLP-1 prescription filled within 6 months of first using FreeStyle Libre


Measurement:

- Change in HbA1c from the time of first using FreeStyle Libre to 6 months later



Overall Results


Patients who were already using a GLP-1 saw a significant ($p < 0.001$) improvement in HbA1c after adding FreeStyle Libre



Gray bar represents baseline HbA1c measurement just before adding Libre
Blue bar represents follow-up HbA1c measurement 6 months after adding Libre

Results: By Time Gap Between Starting GLP-1 and Adding FreeStyle Libre


Regardless of the time gap between starting GLP-1 therapy and adding FreeStyle Libre, a significant ($p < 0.001$) benefit was seen by adding FreeStyle Libre to the treatment regimen



Gray bars represent baseline HbA1c measurements just before adding Libre
Blue bars represent follow-up HbA1c measurements 6 months after adding Libre

Results: By GLP-1 Product Type

Regardless of the GLP-1 product used, patients significantly ($p < 0.001$) benefited from adding FreeStyle Libre




Gray bars represent baseline HbA1c measurements just before adding Libre
Blue bars represent follow-up HbA1c measurements 6 months after adding Libre

Common brand names:

- Semaglutide: Ozempic, Wegovy, Rybelsus
- Dulaglutide: Trulicity
- Other GLP-1s: Adlyxin, Bydureon, Byetta, Saxenda, Tanzeum, Victoza, Xultophy, Soliqua

Results: By User Type

Both insulin users and non-insulin users significantly ($p < 0.001$) benefited from adding FreeStyle Libre



Gray bars represent baseline HbA1c measurements just before adding Libre
Blue bars represent follow-up HbA1c measurements 6 months after adding Libre

Patient Characteristics

N=1,781 adults with Type 2 diabetes who were on GLP-1 therapy and then added FreeStyle Libre

Patient Characteristics	
Age (years)	55 ± 10
Male	930 (52%)
Female	851 (48%)
Race:	
African American	286 (16%)
Asian	35 (2%)
Caucasian	1,279 (72%)
Other/unknown	181 (10%)
Insulin Use:	
MDI (multiple daily injections)	675 (38%)
Basal Insulin	563 (32%)
No Insulin	543 (30%)
GLP-1 Use:	
Semaglutide	401 (23%)
Dulaglutide	771 (43%)
Other GLP-1	609 (34%)
Baseline HbA1c (%)	9.8 ± 1.5
Median time from 1 st GLP-1 to 1 st FreeStyle Libre	422 days